FINANCINGS

Advaxis Inc. conducted a registered direct offering, generating gross proceeds of approximately $30 million.

Alimera Sciences Inc. closed its underwritten public offering of 18.9 million shares priced at $1.40 each for gross proceeds of $26.5 million.

Avelas Biosciences Inc. raised $20 million in a series C financing round.

Arrowhead Pharmaceuticals Inc. closed its private offering for gross proceeds of $45 million.

Eiger Biopharmaceuticals Inc. priced an underwritten public offering for expected proceeds of $20 million.

Monosol Rx closed a $50 million credit facility with Perceptive Advisors.

Nutrinia Ltd. closed a $30 million series D financing round.

Oncomed Pharmaceuticals Inc. priced an underwritten public offering, which is expected to net approximately $51.4 million.

Recro Pharma Inc. priced an underwritten public offering for gross proceeds of about $15 million.

Samsung Group is taking its Samsung Biologics Co. Ltd. subsidiary public in Korea. The IPO is expected to raise between $1.8 billion to $2.7 billion.

Tioma Therapeutics Inc. raised $86 million in its series A round.

DEALS

Astrazeneca plc completed a licensing agreement with Leo Pharma A/S for the global rights to the interleukin-13 monoclonal antibody tralokinumab in skin diseases.

Bavarian Nordic A/S signed a drug supply agreement with Bristol-Myers Squibb Co. for the supply of Opdivo (nivolumab) for use in a clinical study.

Mayne Pharma Inc. acquired a portfolio of already-marketed dermatology foam assets from Glaxosmithkline plc for $50.1 million.

Scintilla Pharmaceuticals Inc., a subsidiary of Sorrento Therapeutics Inc., has entered a binding term sheet to acquire Semnur Pharmaceuticals Inc., whose lead program is resiniferatoxin for the treatment of intractable cancer pain.

Vyriad Inc. signed a deal with Imanis Life Sciences LLC to develop in vitro and in vivo theranostic tests that assess the probability that a cancer patient will be responsive to Vyriad's oncolytic virus therapeutics.

Xenetic Biosciences Inc. is collaborating with Excivion Ltd. to develop a vaccine against Zika and dengue viruses.

. . . AND MORE

Auris Medical AG's lead drug, Keyzilen (AM-101, esketamine hydrochloride gel), failed the first of two phase III trials in acute inner ear tinnitus.

Chiasma Inc. is reducing its workforce by about 44 percent, primarily in the company's research and general and administrative functions, to lower its operating expenses and extend its cash runway.

Endo International plc said it is withdrawing its supplemental NDA relating to specific abuse-deterrent labeling for Opana ER (extended-release oxymorphone) without prejudice to re-filing.

The U.K. government has moved to end uncertainty about access to European research and development grants following the vote to leave the EU, saying it will underwrite payments on projects that continue beyond the date at which the country finally pulls out.

Tivorsan Pharmaceuticals Inc. said the FDA granted orphan drug designation to its lead candidate, human recombinant biglycan, to treat Duchenne muscular dystrophy.

Vertex Pharmaceuticals Inc. is ending a phase III study testing VX-661 with its already-approved Kalydeco (ivacaftor) in a hard-to-treat subgroup of cystic fibrosis patients after the combination failed to deliver a pre-specified improvement in lung function.